Hemocompatibility is one of the major criteria for the
successful
cardiovascular applicability of novel biomaterials. In this context,
monolayers of certain biomolecules can be used to improve surface
biocompatibility. To this end, biocoatings incorporating a phospholipid
(1,2-dioleoyl-
sn
-glycero-3-phosphocholine, DOPC),
an immunosuppressant (cyclosporine A, CsA), and an antioxidant material
(lauryl gallate, LG) were fabricated by depositing Langmuir films
onto gold or mica substrates using the Langmuir–Blodgett (LB)
technique. These LB monolayers were thoroughly characterized by means
of quartz crystal microbalance (QCM), atomic force microscopy (AFM),
cyclic voltammetry (CV), and contact angle (CA) measurements. The
obtained results indicate that the properties of these LB films are
modulated by the monolayer composition. The presence of LG in the
three-component systems (DOPC–CsA–LG) increases the
molecular packing and the surface coverage of the substrate, which
affects the wettability of the biocoating. From the different compositions
studied here, we conclude that DOPC–CsA–LG monolayers
with a DOPC/CsA ratio of 1:1 and LG molar fractions of 0.50 and 0.75
exhibit improved surface biocompatible characteristics. These results
open up new perspectives on our knowledge and better understanding
of phenomena at the biomaterial/host interface.